EFFICACY AND SAFETY OF BOSUTINIB IN PATIENTS WITH RESISTANT CHRONIC MYELOID LEUKAEMIA OR INTOLERANT TO ATLEAST 3 INHIBITORS OF PRIOR TYROSINE KINASE

被引：0

作者：

Valentin, Garcia-Gutierrez ^{[1
]}

Dragana, Milojkovic ^{[2
]}

Luis Felipe, Casado ^{[3
]}

Simone, Claudiani ^{[2
]}

Antonio, Jimenez-Velasco ^{[4
]}

Maria Luisa, Marten-Mateos ^{[5
]}

Concepcion, Boque ^{[6
]}

Alejandra, Martinez-Trillo ^{[7
]}

Isabel, Mata ^{[8
]}

Payer Angel, Ramirez ^{[9
]}

Alberto, Alvarez-Larran ^{[10
]}

Elena, Amutio ^{[11
]}

Garcia Abelardo, Barez ^{[12
]}

Guiomar, Bautista ^{[13
]}

Barela Sabela, Bobillo ^{[14
]}

Ruiz Beatriz, Cuevas ^{[15
]}

Pilar, Giraldo ^{[16
]}

Jose Manuel, Puerta ^{[17
]}

Maria Jose, Ramirez ^{[18
]}

Gerosa Silvana, Saavedra ^{[19
]}

Sandra, Valencia ^{[20
]}

Rivas Fernando, Ortega ^{[21
]}

Mas Ana, Rossel ^{[22
]}

Fabio, Ruiz ^{[23
]}

Juan Luis, Steegmann ^{[24
,25
]}

机构：

[1] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[2] Imperial Coll, Hammersmith Hosp, London, England

[3] Hosp Virgen de la Salud, Toledo, Spain

[4] 8Hosp Univ Carlos Haya, Malaga, Spain

[5] Hosp San Pedro de Alcantara, Serv Hematol, Caceres, Spain

[6] Insitute Cotele Oncol, Barcelona, Spain

[7] Hosp Clin Barcelona, Serv Hematol, Barcelona, Spain

[8] Hosp Costa Sol, Malaga, Spain

[9] Hosp Univ Cent Asturias, Oviedo, Spain

[10] Hosp del Mar, Serv Hematol, Barcelona, Spain

[11] Hosp Cruces, Vizcaya, Spain

[12] Hosp Nuestra Senora Sonsoles, Serv Hematol, Avila, Spain

[13] Hosp Univ Puerta de Hierro, Serv Hematol, Majadahonda, Spain

[14] Hosp Valle De Hebron, Barcelona, Spain

[15] Hosp Univ Burgos, Burgos, Spain

[16] Miguel Servet Univ Hosp, Haematol, Zaragoza, Spain

[17] Hosp Univ Virgen de las Nieves, Unidad Gest Clin Hematol & Hemoterapia, Granada, Spain

[18] Hosp Jerez Frontera, Serv Hematol, Cadiz, Spain

[19] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[20] Hosp Segovia, Serv Hematol, Segovia, Spain

[21] Hosp Palencia, Hematol 29Serv, Palencia, Spain

[22] 33Hosp Virgen de la Victoria, Malaga, Spain

[23] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[24] Hosp Princesa, Hematol, Madrid, Spain

[25] Hosp Princesa, IIS IP, Madrid, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-126

引用

页码：79 / 80

页数：2

共 50 条

[1] Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study.
Saussele, Susanne
Gambacorti-Passerini, Carlo
Gutierrez, Valentin Garcia
Abboud, Camille N.
Purcell, Simon
Viqueira, Andrea
Leip, Eric
Ernst, Thomas
Giles, Frank
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Bruemmendorf, Tim H.
Cortes, Jorge E.
Khoury, Hanna J.
Kantarjian, Hagop M.
Kim, Dong-Wook
Schafhausen, Philippe
Conlan, Maureen G.
Shapiro, Mark
Turnbull, Kathleen
Leip, Eric
Gambacorti-Passerini, Carlo
Lipton, Jeff H.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (01) : 97 - 110
[3] Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
Tinsley, Sara M.
JOURNAL OF CLINICAL NURSING, 2010, 19 (9-10) : 1207 - 1218
[4] Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata, Roberto
Attolico, Immacolata
Trawinska, Malgorzata Monika
Capodanno, Isabella
Annunziata, Mario
Elena, Chiara
Luciano, Luigiana
Crugnola, Monica
Bergamaschi, Micaela
Bonifacio, Massimiliano
Barate, Claudia
Mauro, Endri
Binotto, Gianni
Sgherza, Nicola
Aguzzi, Chiara
Monteleone, Barbara
Sora, Federica
Caocci, Giovanni
Luzi, Debora
Mariggio, Elena
Scaffidi, Luigi
Cattaneo, Daniele
Gozzini, Antonella
Di Veroli, Ambra
Abruzzese, Elisabetta
Galimberti, Sara
Iurlo, Alessandra
Specchia, Giorgina
Breccia, Massimo
HEMATOLOGICAL ONCOLOGY, 2021, 39 (03) : 401 - 408
[5] Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
Takahashi, Naoto
Nakaseko, Chiaki
Kobayashi, Yukio
Miyamura, Koichi
Ono, Chiho
Koide, Yuichiro
Fujii, Yosuke
Ohnishi, Kazunori
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (03) : 398 - 410
[6] Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
Naoto Takahashi
Chiaki Nakaseko
Yukio Kobayashi
Koichi Miyamura
Chiho Ono
Yuichiro Koide
Yosuke Fujii
Kazunori Ohnishi
International Journal of Hematology, 2017, 106 : 398 - 410
[7] Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Garcia-Gutierrez, Valentin
Carlos Hernandez-Boluda, Juan
FRONTIERS IN ONCOLOGY, 2019, 9
[8] CHRONIC MYELOID LEUKAEMIA (CML): EVALUATION OF EFFICACY OF THE TREATMENT WITH INHIBITORS OF TYROSINE KINASE (ITK) IN 31 PATIENTS
Garcia Susana, Ramirez
Jimenez Isabel, Vazquez-Pastor
Juan Nicolas, Rodriguez Rodriguez
Vallellano Antonio, Palma
Esparraga Encarnacion, Gil
Korrecha Karoll, Gomez
Yasmina, Skiredj
Bautista Rocio, Zapata
Maria Antonia, Ruiz Cobos
HAEMATOLOGICA, 2016, 101 : 351 - 351
[9] Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib
Liu, Yuntao
Yang, Yunfan
Sun, Hui
Meng, Li
Lin, Hai
Chen, Chunyan
Hu, Jianda
Shen, Xuliang
Duan, Minghui
Zhang, Yanli
Abulaiti, Dilinazi
Wang, Jinghua
Zhu, Hongqian
Hua, Luoming
Leng, Qing
Zhang, Chun
Sun, Lili
Li, Weiming
Zhu, Huanling
Liu, Bingcheng
Wang, Jianxiang
BLOOD, 2023, 142
[10] Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
Anna Rychter
Piotr Jerzmanowski
Adam Hołub
Zofia Specht-Szwoch
Violetta Kalinowska
Urszula Tęgowska
Ilona Seferyńska
Agnieszka Kołkowska-Leśniak
Ewa Lech-Marańda
Joanna Góra-Tybor
Medical Oncology, 2017, 34

← 1 2 3 4 5 →